We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter describes the epidemiology, clinical diagnosis, and clinical significance of Fetal and neonatal alloimmune thrombocytopenia (FNAIT) in pregnancy. FNAIT is the commonest cause of severe neonatal thrombocytopenia, and is analogous to the fetal/neonatal anemia caused by hemolytic disease of the fetus and newborn (HDFN). FNAIT is usually suspected in neonates with bleeding or severe, unexplained, and/or isolated postnatal thrombocytopenia. The strategies for ante-natal treatment have included the use of serial platelet transfusions, which while effective are invasive and associated with significant morbidity and mortality. Significant recent progress has involved refinement of maternal treatment, stratifying it according to the likely severity of FNAIT based on the history in previous pregnancies. However, the ideal ante-natal treatment, which is effective without causing significant side-effects to the mother or fetus, has yet to be determined, and further clinical trials are needed.
Thrombocytopenia in the mother and fetus is a common problem. This chapter reviews its causes, clinical significance, investigation and management. Thrombocytopenia complicating hypertensive disorders of pregnancy is responsible for about 20% of cases of maternal thrombocytopenia. The pregnancy-related causes of disseminated intravascular coagulation (DIC) include pre-eclampsia, placental abruption, amniotic fluid embolism and, rarely, retention of a dead fetus. Immune thrombocytopenia is responsible for about 4% of maternal thrombocytopenia. Most cases are due to idiopathic autoimmune thrombocytopenia, but some are drug-related and some associated with HIV infection. Neonatal thrombocytopenia has many causes, and is the most common haematological problem in the newborn infant, and probably the fetus as well. A better understanding of the risks of thrombocytopenia in pregnancy to the mother and fetus has resulted in better targeting of treatment: withholding it in low-risk situations and using intensive therapy where there is high risk.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.